Published Date: August, 2017
Figure : Global Conjunctivitis Market by projection
The Global Conjunctivitis Market is projected to grow with a CAGR between 2.1% and 2.5% during 2016-2022 and reach USD X.XX billion by 2022. Conjunctivitis or pink eye is an inflammation or redness of the lining of the white part of the eye and the underside of the eyelid that can be caused by infection, allergic reaction, or physical agents like infrared or ultraviolet light. Conjunctivitis is an extremely common eye problem because the conjunctiva is continually exposed to microorganisms and environmental agents that can cause infections or allergic reactions. It can also affect one or both eyes and, if caused by infection, can be very easily transmitted to others during close physical contact, particularly among children in a daycare center. Thus, people diagnosed with conjunctivitis are recommended not to travel public places for that period of time.
Increasing awareness among patient population about pink eye disease, entry of new drugs and unmet need for viral conjunctivitis are considered to be the key factors driving the growth of this market. Unfavorable government regulations, expiring drug patents of major blockbusters and the growing demand for antibacterial drugs has impacted the demand for branded drugs are the key restraining factors for the growth of this market. Since, there are no approved drugs for the treatment of viral conjunctivitis, many companies are developing drugs which are expected to aid in the treatment of viral conjunctivitis and their effect will turn into a prominent opportunity to promote growth of this market over the forecast period. Moreover, loss of patent exclusivities and increasing demand for generic antibacterial drugs over branded drugs are the major challenges faced by this market.
The report segments the conjunctivitis market by disease type and by region. Market segmentation based on disease type includes Bacterial conjunctivitis, viral conjunctivitis and Allergic conjunctivitis. Furthermore, Allergic conjunctivitis segment is anticipated to grow at the highest CAGR over the forecast period accounted for more than 45% of the total market share by 2022. The key factor driving the growth of allergic conjunctivitis segment, are considered to be the different allergies present in the environment such as cold, acute respiratory infection, or other diseases such as measles, herpes simplex , or herpes zoster.
Geographic Coverage and Analysis:
The report provides regional analysis covering geographies such as North America, Europe, Asia Pacific, Latin America and Rest of the World (RoW). North America along with Latin America accounted for the largest market share together occupying more than 50% share of global market and is expected to continue its dominance over the forecast period. Increasing awareness among the patient and availability of multiple treatment options are expected to drive the growth in this region. Moreover, Asia Pacific is anticipated to grow at the highest CAGR over the forecast period and provides the opportunity for market growth due to presence of major players and increasing R&D activities.
The companies covered in the report include
The report provides deep insights on demand forecasts, market trends and micro and macro indicators. In addition, this report provides insights on the factors that are driving and restraining the demand of conjunctivitis globally as well as regionally. Moreover, IGR-Growth Matrix analysis given in the report brings an insight on the investment areas that existing or new market players can consider.
The report provides insights into the market using analytical tools such as Porter’s five forces analysis and value chain analysis of conjunctivitis market. Moreover, the study highlights current market trends and provides forecast from 2016 to 2022. We also have highlighted future trends in the conjunctivitis market that will impact the demand during the forecast period. Moreover, the competitive analysis given in each regional market brings an insight on the market share of the leading players. Additionally, the analysis highlights rise and fall in the market shares of the key players in the market.
The report also provides in depth analysis of regulatory framework pertaining to Conjunctivitis Market. This will help the companies to understand the regulatory compliances, supports, barriers in the Conjunctivitis market. This section highlights key amendments and their implication on Conjunctivitis market in the short run as well as in the long run.
1. Report Overview
1.1 Report Description
1.2 Research Methods
1.3 Research Approaches
2. Executive Summary
3. Conjunctivitis Market Overview
3.2 Market Dynamics
3.7 Porter’s Five Forces Analysis
3.8 IGR – Growth Matrix Analysis
3.9 Competitive Landscape in the Conjunctivitis Market
3.10 Regulatory Framework analysis by region
3.10.1 North America
3.10.3 RoW (Including APAC, and LATAM)
4. Global Conjunctivitis Market, by Disease Type, (USD Million) 2015 – 2022
4.2 Bacterial Conjunctivitis
4.3 Viral Conjunctivitis
4.4 Allergic Conjunctivitis
5. Global Conjunctivitis Market, by Region, (USD Million) 2015 – 2022
5.2 North America
5.2.1 North America Conjunctivitis Market, by Disease Type (USD Million)
5.2.2 North America Conjunctivitis Market, by country (USD Million)
5.3.1 Europe Conjunctivitis Market, by Disease Type (USD Million)
5.3.2 Europe Conjunctivitis Market, by country (USD Million)
5.4 Asia Pacific
5.4.1 Asia Pacific Conjunctivitis Market, by Disease Type (USD Million)
5.4.2 Asia Pacific Conjunctivitis Market, by country (USD Million)
5.5 Latin America
5.5.1 Latin America Conjunctivitis Market, by Disease Type (USD Million)
5.5.2 Latin America Conjunctivitis Market, by country (USD Million)
5.6 Rest of the World
5.6.1 RoW Conjunctivitis Market, by Disease Type (USD Million)
6. Leading Companies
6.1 Company Profiles
6.1.3 Allergan, Inc.
6.1.4 Bausch & Lomb
6.1.5 Celsus Therapeutics
6.1.6 Eleven Biotherapeutics
6.1.7 Griffin Discoveries
6.1.12 Ocular Therapeutix
6.1.13 Santen Pharmaceuticals
6.1.15 Sun Pharma
6.1.16 Pfizer, Inc.